专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4409327A Process and reagent for the determination of the biological activity of heparin in plasma 失效
标题翻译：用于测定血浆中肝素生物活性的方法和试剂
公开(公告)号：US4409327A
公开(公告)日：1983-10-11
申请号：US233536
申请日：1981-02-11
申请人： Knut Bartl , Helmut Lill , Peter Roeschlau , Joachim Ziegenhorn
发明人： Knut Bartl , Helmut Lill , Peter Roeschlau , Joachim Ziegenhorn
IPC分类号： G01N33/66 , C12Q1/37 , C12Q1/56 , G01N33/50 , G01N33/86 , C12Q1/38
CPC分类号： G01N33/86 , C12Q2337/12 , G01N2333/8117 , G01N2333/96444 , G01N2333/974 , G01N2400/40 , Y10S435/81
摘要： Method and reagent for the determination of the biological activity of heparin in plasma by adding thrombin or Factor X.sub.a as the proteolytic enzyme and a chromogen substrate of the latter and measuring the dye liberated from the chromogen substrate in the absence of exogenous anti-thrombin III, the improvement consisting of adding, additionally, at least one compound of the formula ##STR1## wherein X is oxygen or the group NR.sub.5 ;and R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently selected from hydrogen or alkyl of 1 to 2 carbon atoms.
摘要翻译：通过添加凝血酶或因子Xa作为蛋白水解酶和后者的色底物，测定血浆中肝素生物活性的方法和试剂，并测定在没有外源性抗凝血酶III条件下从色底物释放的染料，该改进包括另外加入至少一种式（IMAGE）化合物，其中X是氧或NR5基团; 并且R 1，R 2，R 3，R 4和R 5独立地选自氢或1至2个碳原子的烷基。

2. 发明申请

US20180243369A1 ALPHA-1-MICROGLOBULIN FOR USE IN THE PROTECTION OF KIDNEYS IN RADIONUCLIDE THERAPY 审中-公开
公开(公告)号：US20180243369A1
公开(公告)日：2018-08-30
申请号：US15552478
申请日：2016-02-25
申请人： A1M PHARMA AB
发明人： Bo Akerstrom , Sven-Erik STRAND , Magnus Göran GRAM , Amanda Thuy TRAN
IPC分类号： A61K38/17 , A61K51/08 , A61P13/12
CPC分类号： A61K38/1722 , A61K51/08 , A61K51/083 , A61P13/12 , G01N2333/8117 , Y02A50/473
摘要： This invention relates to α1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.

3. 发明申请

US20020127730A1 Method for performing activated clotting time test with reduced sensitivity to the presence of aprotinin and for assessing aprotinin sensitivity 失效
标题翻译：进行活化凝血时间试验的方法，对抑肽酶的存在具有降低的敏感性并用于评估抑肽酶敏感性
公开(公告)号：US20020127730A1
公开(公告)日：2002-09-12
申请号：US09753974
申请日：2001-01-03
发明人： Jennifer C. Aiken , Jon H. Henderson , Barbara A. DeBiase
IPC分类号： G01N033/86
CPC分类号： G01N33/86 , G01N2333/8117 , G01N2400/40
摘要： A coagulation test for determining the activated clotting time (ACT) of blood in the presence of heparin that produces test results that are substantially insensitive to the drug aprotinin. The activator is formulated to be a combination of celite and bentonite. The ACT results obtained with this formulation are similar to celite ACT tests on heparinized blood while simultaneously being unaffected by aprotinin. Additionally, a method for quantifying the aprotinin effect of different ACT formulations is disclosed.
摘要翻译：用于确定在肝素存在下的血液的活化凝血时间（ACT）的凝血试验，其产生对药物抑肽酶基本不敏感的测试结果。活化剂配制成硅藻土和膨润土的组合。用该制剂获得的ACT结果与肝素化血液的硅藻土ACT测试相似，同时不受抑肽酶的影响。另外，公开了用于定量不同ACT制剂的抑肽酶作用的方法。

4. 发明授权

US08771714B2 Systems and methods for in vivo measurement of interstitial biological activity, processes and/or compositions 有权
标题翻译：用于体内测量间质生物活性，方法和/或组合物的系统和方法
公开(公告)号：US08771714B2
公开(公告)日：2014-07-08
申请号：US12513116
申请日：2007-10-31
申请人： Francis G. Spinale , Robert Stroud , Michael Looper , Anne Deschamps
发明人： Francis G. Spinale , Robert Stroud , Michael Looper , Anne Deschamps
IPC分类号： A61K9/00 , A61B5/0275 , C12Q1/34 , C12Q1/37 , C12Q1/06 , G01N33/574 , G01N33/573 , G01N33/00 , A61K51/00
CPC分类号： C12Q1/37 , A61B5/0071 , A61B5/1451 , A61B5/1459 , A61K49/0019 , A61K49/0056 , C07K7/06 , G01N2333/8117
摘要： Provided are systems and methods for detecting and/or measuring in vivo interstitial biological activity, processes, and or compounds in human or animal subjects.
摘要翻译：提供了用于检测和/或测量人或动物受试者体内间质生物活性，过程和/或化合物的系统和方法。

5. 发明授权

US07943333B2 Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity 有权
标题翻译：基于FSAP活性差异调节的鉴定因子VII活化蛋白酶（FSAP）的Marburg I变体载体的诊断方法
公开(公告)号：US07943333B2
公开(公告)日：2011-05-17
申请号：US11642747
申请日：2006-12-21
申请人： Frank Vitzthum , Herbert Schwarz
发明人： Frank Vitzthum , Herbert Schwarz
IPC分类号： C12Q1/37 , C12Q1/56 , G01N33/573 , G01N33/86
CPC分类号： G01N33/6893 , C12Q1/37 , C12Q1/56 , G01N33/86 , G01N2333/8117 , G01N2333/96447
摘要： The present invention relates to a diagnostic method for identifying persons with genetically related hetero- or homozygous expression of the MR I variant of factor VII-activating protease (FSAP). The heterozygous or homozygous presence of an MR I polymorphism can be identified by a differential modulation of the FSAP activity.
摘要翻译：本发明涉及用于识别因子VII活化蛋白酶（FSAP）的MRI变体的遗传相关杂合或纯合表达的人的诊断方法。可以通过FSAP活性的差异调制来鉴定MR I多态性的杂合或纯合存在。

6. 发明申请

US20090042800A1 ASSAY 有权
标题翻译：测定
公开(公告)号：US20090042800A1
公开(公告)日：2009-02-12
申请号：US12252323
申请日：2008-10-15
申请人： Ivan Mikhailovich PETYAEV
发明人： Ivan Mikhailovich PETYAEV
IPC分类号： A61K38/36 , G01N33/563 , A61P7/00 , A61P29/00 , A61P31/00
CPC分类号： A61K38/57 , G01N33/6857 , G01N2333/8117
摘要： A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired immune response or opportunistic infection. The invention also provides the use of a trypsin inhibitor in the manufacture of a medicament for use in the treatment or prevention of a disorder associated with elevated trypsin activity which is correlated with IgG fragmentation or modification.
摘要翻译：一种用于确定患有炎症，机会性感染或免疫球蛋白代谢破坏的个体的风险的方法，包括（a）确定取自个体的样品中免疫球蛋白的Fc功能的断裂或修饰水平，以及（b）确定从而导致炎症的风险，免疫反应受损或机会性感染。本发明还提供了胰蛋白酶抑制剂在制备用于治疗或预防与IgG断裂或修饰相关的升高的胰蛋白酶活性相关疾病的药物中的用途。

7. 发明授权

US06632678B2 Method for performing activated clotting time test with reduced sensitivity to the presence of aprotinin and for assessing aprotinin sensitivity 失效
标题翻译：进行活化凝血时间试验的方法，对抑肽酶的存在具有降低的敏感性并用于评估抑肽酶敏感性
公开(公告)号：US06632678B2
公开(公告)日：2003-10-14
申请号：US09753974
申请日：2001-01-03
申请人： Jennifer C. Aiken , Jon H. Henderson , Barbara A. DeBiase
发明人： Jennifer C. Aiken , Jon H. Henderson , Barbara A. DeBiase
IPC分类号： G01N3386
CPC分类号： G01N33/86 , G01N2333/8117 , G01N2400/40
摘要： A coagulation test for determining the activated clotting time (ACT) of blood in the presence of heparin that produces test results that are substantially insensitive to the drug aprotinin. The activator is formulated to be a combination of celite and bentonite. The ACT results obtained with this formulation are similar to celite ACT tests on heparinized blood while simultaneously being unaffected by aprotinin. Additionally, a method for quantifying the aprotinin effect of different ACT formulations is disclosed.
摘要翻译：用于确定在肝素存在下的血液的活化凝血时间（ACT）的凝血试验，其产生对药物抑肽酶基本不敏感的测试结果。活化剂配制成硅藻土和膨润土的组合。用该制剂获得的ACT结果与肝素化血液的硅藻土ACT测试相似，同时不受抑肽酶的影响。另外，公开了一种用于量化不同ACT制剂的抑肽酶作用的方法

8. 发明授权

US5906942A Method for preparing stable coagulation controls 失效
标题翻译：制备稳定凝血控制的方法
公开(公告)号：US5906942A
公开(公告)日：1999-05-25
申请号：US927894
申请日：1997-09-11
申请人： Roy E. Speck
发明人： Roy E. Speck
IPC分类号： C12Q1/56 , G01N33/86 , G01N33/96
CPC分类号： C12Q1/56 , G01N33/86 , G01N33/96 , G01N2333/755 , G01N2333/8117 , G01N2333/96444 , G01N2333/974 , G01N2496/05 , Y10T436/10 , Y10T436/101666 , Y10T436/106664 , Y10T436/108331
摘要： A method for preparing a coagulation control sample which is stable in the absence of buffer and which has a clotting time within the range of normal human clotting times for reproducibly monitoring coagulation capability in a human patient comprising (a) collecting blood from a mammalian animal, (b) removing red blood cells from the blood to produce mammalian plasma, and (c) adding to the plasma an amount of at least one non-primate mammalian plasma that has been adsorbed with a coagulation factors II, VII, IX and X adsorbent prior to addition of the plasma to the mammalian plasma.
摘要翻译：一种制备凝血对照样品的方法，其在不存在缓冲液的情况下是稳定的，并且其凝结时间在正常人凝血时间范围内，用于可重复地监测人患者的凝血能力，包括（a）从哺乳动物收集血液，（b）从血液中除去红细胞以产生哺乳动物血浆，和（c）向血浆中加入一定量的至少一种吸附了凝血因子II，VII，IX和X吸附剂的非灵长类哺乳动物血浆之前将等离子体加入到哺乳动物血浆中。

9. 发明授权

US4753875A Method for assaying proteases with tagged proteinaceous inhibitors 失效
标题翻译：用标记蛋白质抑制剂测定蛋白酶的方法
公开(公告)号：US4753875A
公开(公告)日：1988-06-28
申请号：US759355
申请日：1985-07-26
申请人： James W. Ryan
发明人： James W. Ryan
IPC分类号： C12Q1/37 , G01N33/573 , C12N9/99 , C12Q1/38 , C12Q1/56
CPC分类号： G01N33/573 , C12Q1/37 , G01N2333/8117 , G01N2333/8142 , G01N2333/815 , G01N2333/96455 , G01N2333/96472
摘要： A new and useful method for assaying proteases, in which an excess of tagged proteinaceous inhibitor of a protease is mixed in solution with a sample containing the protease to form a mixture of a tagged inhibitor-protease complex and free tagged inhibitor. The complex is separated from the tagged inhibitor and the tag measured. Alternatively, anti-protease antibody may be added to bind the complex so that assay specificity and/or separation is enhanced. The method of this invention is applicable to assaying minute quantities of clinically significant proteases e.g. renin, kallikrein, thrombin occurring in serum, plasma, urine and other tissues.
摘要翻译：用于测定蛋白酶的新的和有用的方法，其中过量的蛋白酶标记的蛋白质抑制剂在溶液中与含有蛋白酶的样品混合以形成标记的抑制剂 - 蛋白酶复合物和游离标记的抑制剂的混合物。将复合物与标记的抑制剂分离并测量标签。或者，可以加入抗蛋白酶抗体以结合复合物，使得测定特异性和/或分离增强。本发明的方法适用于测定微量的临床显着蛋白酶，例如，肾素，激肽释放酶，凝血酶发生在血清，血浆，尿液和其他组织中。

10. 发明申请

US20070248989A1 Method and Kit for the Early Detection of Impaired Renal Status 有权
标题翻译：早期检测肾损伤状态的方法和试剂盒
公开(公告)号：US20070248989A1
公开(公告)日：2007-10-25
申请号：US11737326
申请日：2007-04-19
申请人： Prasad Devarajan
发明人： Prasad Devarajan
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2333/70539 , G01N2333/8117 , G01N2800/347
摘要： A method and kit for identifying the presence of an early biomarker of impaired renal status following a renal event in a mammalian subject. The method typically comprises (a) providing a body fluid sample obtained from a mammalian subject following a renal event; and (b) detecting in the provided sample the presence of a protein selected from the group consisting of aprotinin, alpha-1-microglobulin (A1M), alpha-1-acid-glycoprotein (A1AG), microalbumin, and combinations thereof, the presence thereof serving as an early biomarker of a change in renal status. The method can include a kit for point-of-care detection of the early biomarker of impaired renal status. Identification of the presence or absence of the early biomarker typically directs a caregiver's therapeutic decision regarding managing treatment of the subject for impaired renal status The invention also includes a method of assessing the administration of aprotinin during cardiopulmonary bypass surgery and provides for methods where the level of aprotinin in the subject's urine directs a caregiver's therapeutic decision regarding the intra-operative administration of aprotinin.
摘要翻译：用于鉴定哺乳动物受试者肾脏事件后肾脏状态受损的早期生物标志物的存在的方法和试剂盒。该方法通常包括（a）在肾事件之后提供从哺乳动物受试者获得的体液样品; （b）在提供的样品中检测选自抑肽酶，α-1-微球蛋白（A1M），α-1-酸 - 糖蛋白（A1AG），微量白蛋白及其组合的蛋白质的存在，其作为肾脏状态改变的早期生物标志物。该方法可以包括用于对受损的肾状态的早期生物标志物进行护理点检测的试剂盒。识别早期生物标志物的存在或不存在通常指导照顾者关于管理受试者对肾脏受损的治疗的治疗决定。本发明还包括在体外循环手术期间评估抑肽酶的施用的方法，并且提供了一种方法，受试者尿液中的抑肽酶指导了护理人员关于抑肽酶术中给药的治疗决定。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式